{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:14:00Z","timestamp":1783948440284,"version":"3.55.0"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Galectins, \u03b2-galactoside-binding proteins, function as key regulators in pathological transitions, bridging tissue homeostasis to oncogenesis and inflammation through intracellular and extracellular mechanisms. Notably, they play a pivotal role in the pathogenesis of leukemia by interacting with glycoconjugates to promote tumor progression. Among them, Galectin-1 (Gal-1), Gal-3, and Gal-9 have been associated with multiple leukemia subtypes, such as acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), B-cell precursor acute lymphoblastic leukemia (BCP-ALL), adult T-cell leukemia (ATL), and chronic lymphocytic leukemia (CLL). These galectins contribute to leukemic cell survival by modulating extracellular matrix (ECM) interactions, suppressing anti-tumor immune responses, and promoting immune escape. Their involvement in sustaining leukemic proliferation and immune evasion highlights their potential as therapeutic targets. Recent advancements in the development of galectin inhibitors provide promising avenues to disrupt these oncogenic pathways. However, distinct galectin isoform pathologies across diseases require highly selective therapeutics, and substantial carbohydrate recognition domain (CRD) structural homology combined with conserved \u03b2-D-galactopyranoside-binding mechanisms complicates specific inhibitor design. This review summarizes galectin-mediated mechanisms in leukemia biology, evaluates the potential of galectin-targeted therapies and offers insights for the development of specific inhibitors of Gal-1, -3, and -9 to promote clinical management and treatment efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1685266","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:16:50Z","timestamp":1758773810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Galectins-1, -3 and -9 in leukemia: mechanistic insights and therapeutic translation"],"prefix":"10.3389","volume":"16","author":[{"given":"Tianning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.11.003","article-title":"Translating the \u2018Sugar code\u2019 into immune and vascular signaling programs","volume":"42","author":"Cerliani","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-023-00636-2","article-title":"Targeting galectin-driven regulatory circuits in cancer and fibrosis","volume":"22","author":"Mari\u00f1o","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.02.008","article-title":"Untangling galectin-driven regulatory circuits in autoimmune inflammation","volume":"24","author":"Toscano","year":"2018","journal-title":"Trends Mol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182041","article-title":"Sweetening the hallmarks of cancer: galectins as multifunctional mediators of tumor progression","volume":"217","author":"Girotti","year":"2020","journal-title":"J Exp Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3870","article-title":"Impact of galectins in resistance to anticancer therapies","volume":"26","author":"Navarro","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010210","article-title":"Galectin targeted therapy in oncology: current knowledge and perspectives","volume":"19","author":"Wdowiak","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102847","article-title":"Emerging role of galectin family in inflammatory autoimmune diseases","volume":"20","author":"Xu","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.06.001","article-title":"Targeting galectin-3 in inflammatory and fibrotic diseases","volume":"44","author":"Bouffette","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jbior.2018.09.003","article-title":"Galectins as regulators of cell survival in the leukemia niche","volume":"71","author":"Ruvolo","year":"2019","journal-title":"Adv Biol Regul"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328362370f","article-title":"Galectins in hematological Malignancies","volume":"20","author":"Giordano","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.11.019","article-title":"Galectins as potential emerging key targets in different types of leukemia","volume":"844","author":"Zheng","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118785","article-title":"Lgals1 acts as a pro-survival molecule in aml","volume":"1867","author":"Ruvolo","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06865-6","article-title":"A novel lgals1-depended and immune-associated fatty acid metabolism risk model in acute myeloid leukemia stem cells","volume":"15","author":"Qin","year":"2024","journal-title":"Cell Death Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01789-6","article-title":"Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia","volume":"37","author":"Li","year":"2022","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114835","article-title":"Galectin-1: an important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target","volume":"158","author":"Liu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-09-2765","article-title":"Mll-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1","volume":"16","author":"Juszczynski","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.315","article-title":"Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1","volume":"27","author":"Croci","year":"2012","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj7552","article-title":"A Proinflammatory Stem Cell Niche Drives Myelofibrosis through a Targeta ble Galectin-1 Axis","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474569","article-title":"Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical hodgkin lymphoma","volume":"121","author":"Ouyang","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327346","article-title":"Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed\/refractory disease in classical hodgkin lymphoma","volume":"117","author":"Kamper","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.395152","article-title":"Structural basis for galectin-1-dependent pre-B cell receptor (Pre-bcr) activation","volume":"287","author":"Elantak","year":"2012","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaf3949","article-title":"Dynamic pre-bcr homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia","volume":"9","author":"Erasmus","year":"2016","journal-title":"Sci Signal"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106385","article-title":"Niche-expressed galectin-1 is involved in pre-B acute lymphoblastic leukemia relapse through pre-B cell receptor activation","volume":"26","author":"Pelletier","year":"2023","journal-title":"iScience"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18285","article-title":"T-helper cell regulation of cd45 phosphatase activity by galectin-1 and cd43 governs chronic lymphocytic leukaemia proliferation","volume":"198","author":"Imbery","year":"2022","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5114\/ceji.2021.105246","article-title":"Immunomodulatory effects of galectin-1 in patients with chronic lymphocytic leukemia","volume":"46","author":"Kostic","year":"2021","journal-title":"Cent Eur J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706017104","article-title":"The ap1-dependent secretion of galectin-1 by reed\u2013sternberg cells fosters immune privilege in classical hodgkin lymphoma","volume":"104","author":"Juszczynski","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.3962.3962","article-title":"Robust bioinformatics approach for identifying novel aml lsc targets: putative role of galectin-1 in the immune-microenvironment","volume":"130","author":"Herbrich","year":"2017","journal-title":". Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8489","article-title":"Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells","volume":"7","author":"Luo","year":"2016","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04832-x","article-title":"Myeloid leukemia-derived galectin-1 downregulates car expression to hinder cytotoxicity of car T cells","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2948-3","article-title":"Clinical impact of galectin-3 in newly diagnosed T (15;17)(Q22;Q21)\/pml-rara acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens","volume":"96","author":"Gao","year":"2017","journal-title":"Ann Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1243677","article-title":"Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: A retrospective cohort study with long-term follow-up and formulation of risk scoring system","volume":"58","author":"Gao","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443762","article-title":"Higher bone marrow lgals3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia","volume":"121","author":"Cheng","year":"2013","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.05.025","article-title":"Lgals3 is connected to cd74 in a previously unknown protein network that is associated with poor survival in patients with aml","volume":"44","author":"Ruvolo","year":"2019","journal-title":"EBioMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2018.04.005","article-title":"Role of msc-derived galectin 3 in the aml microenvironment","volume":"1865","author":"Ruvolo","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000193223","article-title":"Increased serum 90k and galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas","volume":"120","author":"Kim","year":"2008","journal-title":"Acta Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-014-0099-8","article-title":"Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via wnt\/\u03b2-catenin signaling pathway","volume":"8","author":"Hu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jbior.2017.05.001","article-title":"Gsk-3 as a novel prognostic indicator in leukemia","volume":"65","author":"Ruvolo","year":"2017","journal-title":"Adv Biol Regul"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1111138108","article-title":"Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia","volume":"108","author":"Yamamoto-Sugitani","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.026","article-title":"Suppression of serpina1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells","volume":"38","author":"Nakayama","year":"2014","journal-title":"Leuk Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/s0002-9440(10)63177-x","article-title":"An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas","volume":"164","author":"Hoyer","year":"2004","journal-title":"Am J Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438234","article-title":"Galectin-3 binds to cd45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death","volume":"120","author":"Clark","year":"2012","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583062","article-title":"Mer tyrosine kinase promotes the survival of T(1;19)-positive acute lymphoblastic leukemia (All) in the central nervous system (Cns)","volume":"125","author":"Krause","year":"2015","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.arcmed.2022.12.008","article-title":"Effect of acute myeloid leukemia-derived extracellular vesicles on bone marrow mesenchymal stromal cells: expression of poor prognosis genes","volume":"54","author":"Kargar-sichani","year":"2023","journal-title":"Arch Med Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/life15060937","article-title":"Galectin-3 release in the bone marrow microenvironment promotes drug resistance and relapse in acute myeloid leukemia","volume":"15","author":"Y\u0131ld\u0131r\u0131m","year":"2025","journal-title":"Life"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3409","article-title":"B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through galectin-3","volume":"6","author":"Fei","year":"2015","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.175","article-title":"Galectin-3 in pre-B acute lymphoblastic leukemia","volume":"27","author":"Fei","year":"2013","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212167","article-title":"Overcoming microenvironment-mediated chemoprotection through stromal galectin-3 inhibition in acute lymphoblastic leukemia","volume":"22","author":"Tarighat","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7150\/jca.53686","article-title":"Galectin-9 and psmb8 overexpression predict unfavorable prognosis in patients with aml","volume":"12","author":"Zhang","year":"2021","journal-title":"J Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells","volume":"22","author":"Silva","year":"2017","journal-title":"EBioMedicine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1052060","article-title":"Clinical efficacy of azacytidine and venetoclax and prognostic impact of tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience","volume":"13","author":"Giudice","year":"2022","journal-title":"Front Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100013R","article-title":"Activated galectin-9\/tim3 promotes treg and suppresses th1 effector function in chronic lymphocytic leukemia","volume":"35","author":"Pang","year":"2021","journal-title":"FASEB J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05540-8","article-title":"Cxc chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia","volume":"103","author":"Ahmed","year":"2024","journal-title":"Ann Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.853","article-title":"Galectin-9 and myeloid-derived suppressor cell as prognostic indicators for chronic lymphocytic leukemia","volume":"11","author":"Alimu","year":"2023","journal-title":"Immun Inflammation Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9656","article-title":"Increased serum levels of galectin-9 in patients with chronic lymphocytic leukemia","volume":"17","author":"Wdowiak","year":"2019","journal-title":"Oncol Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225370","article-title":"Prognostic potential of galectin-9 mrna expression in chronic lymphocytic leukemia","volume":"15","author":"Bojarska-Junak","year":"2023","journal-title":"Cancers"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267578","article-title":"Tim-3\/gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines","volume":"14","author":"Rezaei","year":"2023","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11898-3","article-title":"Tim-3\/galectin-9 interaction and glutamine metabolism in aml cell lines, hl-60 and thp-1","volume":"24","author":"Shapourian","year":"2024","journal-title":"BMC Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-receptor interactions of galectin-9 and vista suppress human T lymphocyte cytotoxic activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1195535","article-title":"The immune receptor tim-3 acts as a trafficker in a tim-3\/galectin-9 autocrine loop in human myeloid leukemia cells","volume":"5","author":"Gon\u00e7alves Silva","year":"2016","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00375-5","article-title":"Depletion of polyfunctional cd26highcd8+ T cells repertoire in chronic lymphocytic leukemia","volume":"12","author":"Bozorgmehr","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-024-09563-w","article-title":"Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion","volume":"51","author":"Yildirim","year":"2024","journal-title":"Mol Biol Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2012.12.012","article-title":"Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties","volume":"152","author":"Schwitalla","year":"2013","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.07.011","article-title":"A tim-3\/gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression","volume":"17","author":"Kikushige","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4103\/rps.rps_234_23","article-title":"Galectin-9 induces il-1\u03b2 Production as a key inflammatory cytokine in the acute myeloid leukemia cell line (U937)","volume":"20","author":"Behranvand","year":"2025","journal-title":"Res Pharm Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008405","article-title":"Tim-3 signaling hijacks the canonical wnt\/\u03b2-catenin pathway to maintain cancer stemness in acute myeloid leukemia","volume":"7","author":"Sakoda","year":"2023","journal-title":"Blood Adv"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131680","article-title":"Galectin-9 from bone marrow mesenchymal stromal cells mediates immunosuppression on chimeric antigen receptor T cells","volume":"134","author":"Teng","year":"2019","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28839-y","article-title":"Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01787","article-title":"Discovery of selective and orally available galectin-1 inhibitors","volume":"66","author":"Zetterberg","year":"2023","journal-title":"J Med Chem"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11626-011-9462-z","article-title":"Antiproliferative effects of galectin-1 from rana catesbeiana eggs on human leukemia cells and its binding proteins in human cells","volume":"47","author":"Yasumitsu","year":"2011","journal-title":"In Vitro Cell Dev Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3631","article-title":"Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway","volume":"170","author":"Kashio","year":"2003","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01515-w","article-title":"Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance","volume":"9","author":"Choukrani","year":"2023","journal-title":"Cell Death Discov"},{"key":"B72","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/1541-7786.mcr-10-0040","article-title":"Targeting activating transcription factor 3 by galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia","volume":"8","author":"Kuroda","year":"2010","journal-title":"Mol Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.25","article-title":"Galectin-9 exhibits anti-myeloma activity through jnk and P38 map kinase pathways","volume":"24","author":"Kobayashi","year":"2010","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4103\/1735-5362.327507","article-title":"Galectin-9 inhibits cell proliferation and induces apoptosis in jurkat and ke-37 acute lymphoblastic leukemia cell lines via caspase-3 activation","volume":"16","author":"Balajam","year":"2021","journal-title":"Res Pharm Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2241","article-title":"Targeting galectin-1 overcomes paclitaxel resistance in esophageal squamous cell carcinoma","volume":"84","author":"Zhou","year":"2024","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.06.015","article-title":"Otx008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis","volume":"50","author":"Astorgues-Xerri","year":"2014","journal-title":"Eur J Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.3114","article-title":"Zalupski M. A phase I trial of [(1- 4)- linked B-D-mannopyranose]17 - [(1- 6)-linked-a-D- galactopyranose]10 (Davanat) co-administered with 5-fluorouracil, in patients with refractory solid tumors","volume":"23","author":"Fuloria","year":"2005","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002371","article-title":"Enhancing clinical and immunological effects of anti-pd-1 with belapectin, a galectin-3 inhibitor","volume":"9","author":"Curti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203054","article-title":"Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of gr-md-02 in subjects with nash and bridging fibrosis during a phase-2 randomized clinical trial","volume":"13","author":"Harrison","year":"2018","journal-title":"PloS One"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: gr-md-02, a galectin-3 inhibitor, vs. Placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.055","article-title":"A phase 2a, open-label pilot study of the galectin-3 inhibitor gr-md-02 for the treatment of moderate-to-severe plaque psoriasis","volume":"77","author":"Ritchie","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04513-y","article-title":"Safety and pharmacokinetics of gb1211, an oral galectin-3 inhibitor: A single- and multiple-dose first-in-human study in healthy participants","volume":"91","author":"Aslanis","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1250559","article-title":"Resistance to anti-pd-1\/anti-pd-L1: galectin-3 inhibition with gb1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to pd-1\/pd-L1","volume":"14","author":"Mabbitt","year":"2023","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00660","article-title":"Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease","volume":"65","author":"Zetterberg","year":"2022","journal-title":"J Med Chem"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02559-2020","article-title":"Target inhibition of galectin-3 by inhaled td139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2021","journal-title":"Eur Respir J"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05876","article-title":"Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension","volume":"66","author":"Martinez-Martinez","year":"2015","journal-title":"Hypertension"},{"key":"B88","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jacbts.2020.10.006","article-title":"Galectin-3 inhibition with modified citrus pectin in hypertension","volume":"6","author":"Lau","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/nu15163533","article-title":"Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: long-term results of a prospective phase ii study","volume":"15","author":"Keizman","year":"2023","journal-title":"Nutrients"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/nu13124295","article-title":"Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: results of a prospective phase ii study","volume":"13","author":"Keizman","year":"2021","journal-title":"Nutrients"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133840","article-title":"Intra-articular injection of modified citrus pectin and hyaluronate gel induces synergistic effects in treating osteoarthritis","volume":"276","author":"Chen","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2019.100500","article-title":"Blocking extracellular galectin-3 in patients with osteoarthritis","volume":"17","author":"Andrews","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-251660","article-title":"GCS-100, a novel galectin-3 antagonist, modulates mcl-1, noxa, and cell cycle to induce myeloma cell death","volume":"115","author":"Streetly","year":"2010","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0163","article-title":"A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells","volume":"65","author":"Chauhan","year":"2005","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.3286.3286","article-title":"GCS-100, a galectin 3 antagonist, is a novel caspase-9 apoptosis activating agent for the treatment of indolent B-cell Malignancies","volume":"104","author":"Cotter","year":"2004","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02013-z","article-title":"Galectin-3, a novel endogenous trem2 ligand, detrimentally regulates inflammatory response in alzheimer\u2019s disease","volume":"138","author":"Boza-Serrano","year":"2019","journal-title":"Acta Neuropathol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01938-w","article-title":"Alzheimer\u2019s disease: novel targets and investigational drugs for disease modification","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040731","article-title":"An oral galectin inhibitor in covid-19-a phase ii randomized controlled trial","volume":"11","author":"Sigamani","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2024-209848","article-title":"A phase I dose escalation and expansion trial of lyt-200 (a first-in-class anti-galectin-9 antibody) alone and in combination with venetoclax\/hma in relapsed\/refractory aml\/mds","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.482","article-title":"482 phase1\/2 study of an anti-galectin-9 antibody, lyt-200, in patients with metastatic solid tumors","volume":"9","author":"Filipovic","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwl025","article-title":"Galectin-1: A small protein with major functions","volume":"16","author":"Camby","year":"2006","journal-title":"Glycobiology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1021\/jm300014q","article-title":"Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding","volume":"55","author":"Dings","year":"2012","journal-title":"J Med Chem"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0721-7","article-title":"Treatment of B-cell precursor acute lymphoblastic leukemia with the galectin-1 inhibitor ptx008","volume":"37","author":"Paz","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149963","article-title":"Single-cell rna sequencing suggests novel drivers of chronic lymphocytic leukemia patients with ibrutinib resistance","volume":"138","author":"Jin","year":"2021","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7150\/thno.22196","article-title":"Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update","volume":"8","author":"Suthahar","year":"2018","journal-title":"Theranostics"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C112.358002","article-title":"Ligand induced galectin-3 protein self-association","volume":"287","author":"Lepur","year":"2012","journal-title":"J Biol Chem"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.721464","article-title":"Low or no inhibitory potency of the canonical galectin carbohydrate-binding site by pectins and galactomannans","volume":"291","author":"Stegmayr","year":"2016","journal-title":"J Biol Chem"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.904.904","article-title":"GCS-100 induces apoptosis of acute myeloid leukemia cells by disrupting galectin-mediated survival signaling","volume":"124","author":"Davis","year":"2014","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.12.008","article-title":"Combination of galectin inhibitor GCS-100 and bh3 mimetics eliminates both P53 wild type and P53 null aml cells","volume":"1863","author":"Ruvolo","year":"2016","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.4052\/tigg.1744.1SE","article-title":"Clinical trials and applications of galectin antagonists","volume":"30","author":"Girard","year":"2018","journal-title":"Trends Glycosci Glycotechnol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1039\/c9fo00917e","article-title":"Pectin-rich extracts from olives inhibit proliferation of caco-2 and thp-1 cells","volume":"10","author":"Bermudez-Oria","year":"2019","journal-title":"Food Funct"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.116279","article-title":"Leukemia cells apoptosis by a newly discovered heterogeneous polysaccharide fromAngelica sinensis (Oliv.) diels","volume":"241","author":"Liu","year":"2020","journal-title":". Carbohydr Polym"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01296","article-title":"Novel selective galectin-3 antagonists are cytotoxic to acute lymphoblastic leukemia","volume":"65","author":"Bum-Erdene","year":"2022","journal-title":"J Med Chem"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212167","article-title":"Overcoming microenvironment-mediated chemoprotection through stromal galectin-3 inhibition in acute lymphoblastic leukemia","volume":"22","author":"Tarighat","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127768","article-title":"Galectin-9 is a target for the treatment of cancer: A patent review","volume":"254","author":"Rodrigues","year":"2024","journal-title":". Int J Biol macromol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: galectin-9 (Lgals9)","volume":"10","author":"Lv","year":"2023","journal-title":"Genes Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/med.20249","article-title":"Therapeutic potential of galectin-9 in human disease","volume":"33","author":"Wiersma","year":"2011","journal-title":"Med Res Rev"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-008-9251-2","article-title":"Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in lovo colon carcinoma cells","volume":"36","author":"Zhang","year":"2008","journal-title":"Mol Biol Rep"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2018.10.001","article-title":"Galectin\u2013carbohydrate interactions in biomedicine and biotechnology","volume":"37","author":"Laaf","year":"2019","journal-title":"Trends Biotechnol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2016.1163338","article-title":"Galectin-1 inhibitors and their potential therapeutic applications: A patent review","volume":"26","author":"Blanchard","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1139\/cjc-2015-0598","article-title":"Galactose-amidine derivatives as selective antagonists of galectin-9","volume":"94","author":"Mandal","year":"2016","journal-title":"Can J Chem"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00485","article-title":"Discovery of the selective and orally available galectin-1 inhibitor gb1908 as a potential treatment for lung cancer","volume":"67","author":"Zetterberg","year":"2024","journal-title":"J Med Chem"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:16:51Z","timestamp":1758773811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1685266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":122,"alternative-id":["10.3389\/fimmu.2025.1685266"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1685266","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1685266"}}